Moolec Science (NASDAQ: MLEC) restores Nasdaq equity compliance
Rhea-AI Filing Summary
Moolec Science reports that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to the minimum stockholders’ equity standard within the remediation period granted by the Nasdaq Hearings Panel. The company reported stockholders’ equity of approximately $15.2 million as of March 31, 2026 and $11.3 million as of December 31, 2025.
An equity-strengthening step was the partial conversion of preference shares, with ordinary shares valued at $5,473,425 recorded as equity as of December 31, 2025. Moolec’s preliminary March 31, 2026 balance sheet shows total assets around $104 million, including $71.6 million of intangible assets and $16.0 million in investments in joint ventures and associates, alongside borrowings and convertible notes totaling over $70 million.
The company also reflects a pro forma adjustment for $465,161 drawn under a related-party credit line in April 2026 and states that it expects to request conversion of the remaining $4.0 million of preference shares within the next 12 months, which it indicates is expected to further strengthen stockholders’ equity.
Positive
- Regained Nasdaq equity compliance: Moolec reports that it has satisfied the Nasdaq Capital Market’s minimum stockholders’ equity requirement within the Panel’s remediation period, supported by preference share conversion and higher reported equity of approximately $15.2 million as of March 31, 2026.
Negative
- None.
Insights
Moolec has regained Nasdaq equity compliance through balance-sheet strengthening steps.
Moolec Science reports regaining compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement within the Panel’s remediation period. Reported equity of approximately $11.3 million as of December 31, 2025 increased to about $15.2 million as of March 31, 2026, based on unaudited figures.
A key driver was the partial conversion of preference shares, with ordinary shares valued at $5.47 million recorded in equity. The company also notes a related-party credit line draw of $465,161 and indicates it expects to convert the remaining $4.0 million of preference shares within the next 12 months, which it states is expected to further bolster stockholders’ equity.
Moolec’s preliminary balance sheet shows total assets just above $104 million and total liabilities in the low $90 million range, including borrowings and convertible notes exceeding $70 million. Future filings for periods after March 31, 2026 will provide additional clarity on how ongoing financing actions affect equity levels and leverage.
Key Figures
Key Terms
Nasdaq Hearings Panel regulatory
stockholders’ equity requirement financial
payment-in-kind financial
conversion right financial
forward-looking statements regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of May 2026
Commission File Number: 001-41586
MOOLEC SCIENCE SA
(Exact name of Registrant as Specified in Its Charter)
89 Nexus Way, Camana Bay
Grand Cayman KY1-9009
Cayman Islands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
The information contained in this Form 6-K and any exhibits hereto shall be deemed to be incorporated by reference into the Company’s registration statement on Form S-8 (Registration No. 333-282263).
1
EXHIBIT INDEX
The following exhibits are filed as part of this Form 6-K:
| Exhibit | Description | |
| 99.1 | Press release |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Moolec Science SA | ||
| (registrant) | ||
| Date: May 13, 2026 | By: | /s/ Alejandro Antalich |
| Name: | Alejandro Antalich | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period
As previously reported on January 29, 2026, Moolec Science SA (“Moolec” and/or the “Company”), received written notice from the Nasdaq Hearings Panel (the “Panel”) informing the Company that the Panel had granted the Company’s request for an extension to regain compliance with the continued listing requirements of The Nasdaq Stock Market LLC, specifically with respect to the minimum stockholders’ equity requirement.
The Company announced today that it has submitted information required to demonstrate compliance with the Nasdaq Capital Market’s stockholders’ equity requirement within the remediation period granted by the Panel. The Company reported stockholders’ equity of approximately $15.2 million as of March 31, 2026, and approximately $11.3 million as of December 31, 2025. These amounts are reflected in the Company’s unaudited interim condensed consolidated financial statements as of December 31, 2025 and June 30, 2025, and for the six-month periods ended December 31, 2025 and 2024, furnished today to the U.S. Securities and Exchange Commission (“SEC”) on Form 6-K, as well as in the Company’s unaudited preliminary balance sheet as of March 31, 2026 set forth below.
Preliminary Consolidated Condensed Balance Sheet as of March 31, 2026
(Unaudited)
Unaudited historical financial information MLEC as of December 31, 2025 | Unaudited preliminary financial information MLEC as of March 31, 2026 | |||||||
| (amounts in millions of US$) | ||||||||
| Assets | ||||||||
| Intangible assets | 71.6 | 71.6 | ||||||
| Goodwill | 2.1 | 2.1 | ||||||
| Property, plant and equipment | 4.4 | 4.4 | ||||||
| Investment in joint ventures and associates | 16.0 | 16.0 | ||||||
| Cash and cash equivalents | 1.0 | 1.2 | ||||||
| Inventories | 4.0 | 3.6 | ||||||
| Other receivables | 4.2 | 5.2 | ||||||
| Right of use assets | 0.1 | - | ||||||
| Total assets | 103.4 | 104.2 | ||||||
| Equity | ||||||||
| Total equity | 15.2 | 11.3 | ||||||
| Liabilities | ||||||||
| Borrowings | 45.7 | 50.6 | ||||||
| Convertible notes | 20.7 | 21.0 | ||||||
| Trade and other payables | 7.1 | 7.2 | ||||||
| Other liabilities | 0.3 | 0.3 | ||||||
| Deferred tax liabilities | 14.3 | 14.3 | ||||||
| Warrant liabilities | 0.1 | 0.3 | ||||||
| Lease liabilities | 0.1 | - | ||||||
| Total liabilities | 88.2 | 93.4 | ||||||
| Total equity and liabilities | 103.4 | 104.7 | ||||||
Underlying Assumptions
Derecognition Events
The Company assumed the full derecognition of Bioceres S.A. and Bioceres LLC as of December 31, 2025 and determined that the carrying value of the Company’s investment in Theo I SCSp was nil.
Preference Shares Capitalization
The holder of our preference shares issued a notice of conversion to the Company dated December 31, 2025, notifying the Company of the partial exercise of its conversion right under the Subscription Agreement dated December 9, 2024 an aggregate amount of up to $9,000,000, to be converted into ordinary shares in accordance with the conversion formula set out in the Subscription Agreement. The Company notified the holder of the preference shares on December 31, 2025 that the value of the ordinary shares to be issued to the holder as a result of such conversion would be $5,000,000, plus payment-in-kind, for an aggregate amount of $5,473,425. This equity transaction has been reflected in the column “Unaudited historical financial information MLEC as of December 31, 2025” of the table above.
The Company also included as of March 31, 2026 the proforma adjustment related to disbursements made from our current line of credit with one of our related parties for an amount of $465,161 which occurred in April 2026.
Furthermore, the Company expects to notify the holder to convert the remaining $4.0 million of the original aggregate preference share amount within the next 12 months, which is expected to further strengthen stockholders’ equity.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company’s plan to regain compliance under the Nasdaq rules and the related Nasdaq decision, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.